When and how often should PET scans be performed in the management of cervical cancer?
Lai
Chyong-Huey
CH
Yen
Tzu-Chen
TC
D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D003362:Cost-Benefit Analysis; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging*; D008279:Magnetic Resonance Imaging; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging / Q000379:methods; D049268:Positron-Emission Tomography / Q000191:economics; D019275:Radiopharmaceuticals; D016879:Salvage Therapy; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18